Medical Communications

“Don’t conform to what people want – take risks. The people who make a big difference are the ones who …

GlaxoSmithKline veteran, Dave Tudor, is set to take on the role of Managing Director of the Medicines Manufacturing Innovation Centre …

Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …

The biggest news this week came from Israeli biotech Zion Medical after it was announced that HIV drug Gammora was …

Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib …

The NHS in England is now spending over £1billion a year on diabetes prescriptions, almost doubling in the last decade, …

The state of Alabama’s biggest insurer Blue Cross and Blue Shield will no long cover opioid painkiller OxyContin. The decision …

Helena Baker, Vice President of Clinical Strategy at Medical Research Network and a trustee of the newly formed Rare Disease …

The Cambridge based biotechnology firm Bicycle therapeutics, has announced former Pfizer head Dr Phil Jeffrey as the company’s new Senior …

The National Institute for Health and Care Excellence (NICE) has appointed Jeanette Kusel as Director of NICE Scientific Advice. The …

As the US continues to battle the demons in its healthcare system, Donald Trump looks like he may finally make …

Mistrust of the establishment has fuelled anti-vaccine sentiment in recent years, and adherence has waned as a result. Louis Goss …

Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have applications …

Deals dominated the headlines this week as both Sanofi and AstraZeneca made billion dollar agreements. Meanwhile, the FDA gave magic …

Alkermes has been knocked back with the disappointing, though not entirely unexpected, news that the FDA-appointed Psychopharmacologic Drugs Advisory Committee …